HDAC9 and colorectal carcinoma: It is not yet clear whether treatment of variously diagnosed CRC patients with clinically approved HDAC inhibitors in combination with N-acetylated amino acids could help to slow down the tumour development, stop formation of new tumours or metastases, and therefore extend the patients survival.